ZA90983B - Cross-linked antibodies - Google Patents
Cross-linked antibodiesInfo
- Publication number
- ZA90983B ZA90983B ZA90983A ZA90983A ZA90983B ZA 90983 B ZA90983 B ZA 90983B ZA 90983 A ZA90983 A ZA 90983A ZA 90983 A ZA90983 A ZA 90983A ZA 90983 B ZA90983 B ZA 90983B
- Authority
- ZA
- South Africa
- Prior art keywords
- cross
- antibody
- tumour
- conjugates
- linking reagent
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 239000003431 cross linking reagent Substances 0.000 abstract 2
- 229940127121 immunoconjugate Drugs 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB898903022A GB8903022D0 (en) | 1989-02-10 | 1989-02-10 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA90983B true ZA90983B (en) | 1991-10-30 |
Family
ID=10651472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA90983A ZA90983B (en) | 1989-02-10 | 1990-02-09 | Cross-linked antibodies |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0384624B1 (xx) |
| JP (1) | JP2975676B2 (xx) |
| KR (1) | KR910700075A (xx) |
| AT (1) | ATE123952T1 (xx) |
| AU (1) | AU632536B2 (xx) |
| CA (1) | CA2026312A1 (xx) |
| DE (1) | DE69020182T2 (xx) |
| FI (1) | FI904974A0 (xx) |
| GB (2) | GB8903022D0 (xx) |
| HU (1) | HUT56288A (xx) |
| IE (1) | IE67320B1 (xx) |
| IL (1) | IL93361A0 (xx) |
| NO (1) | NO904367L (xx) |
| NZ (1) | NZ232490A (xx) |
| WO (1) | WO1990009195A1 (xx) |
| ZA (1) | ZA90983B (xx) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5194594A (en) * | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| GB9112536D0 (en) * | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| DE19911329A1 (de) * | 1998-03-27 | 2000-09-21 | Benes Ivan Friedrich | Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| US6395511B1 (en) | 1998-11-27 | 2002-05-28 | Darwin Discovery, Ltd. | Nucleic acids encoding a novel family of TGF-β binding proteins from humans |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| EP1419236A4 (en) | 2001-07-24 | 2005-08-03 | Biogen Idec Inc | METHODS OF TREATING OR PREVENTING SCLEROSIS BY USE OF CD2-BINDING AGENTS |
| GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
| JP2005181192A (ja) * | 2003-12-22 | 2005-07-07 | Tacmina Corp | 残留塩素濃度測定方法 |
| EP1750747A1 (en) | 2004-05-07 | 2007-02-14 | Astellas US LLC | Soluble lfa-3 polypeptide for treating viral disorders |
| DE602005025911D1 (de) | 2004-11-22 | 2011-02-24 | Ge Healthcare As | Kontrastmittel für eine extrazelluläre matrix |
| DE102005034950A1 (de) | 2005-07-22 | 2007-02-01 | Tesa Ag | Abroller für die Herstellung eines Klebebandschlauchs |
| ES2354954T3 (es) | 2006-03-22 | 2011-03-21 | Viral Logic Systems Technology Corp. | Métodos para identificar dianas polipeptídicas. |
| US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| CN109310765A (zh) * | 2016-06-20 | 2019-02-05 | 领先基因生物技术股份有限公司 | 抗体-药物偶联物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751286A (en) * | 1985-11-19 | 1988-06-14 | The Johns Hopkins University | Protein label and drug delivery system |
| GB8603537D0 (en) * | 1986-02-13 | 1986-03-19 | Parker D | Conjugate compound |
| GB8720833D0 (en) * | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
-
1989
- 1989-02-10 GB GB898903022A patent/GB8903022D0/en active Pending
-
1990
- 1990-02-09 ZA ZA90983A patent/ZA90983B/xx unknown
- 1990-02-12 KR KR1019900702231A patent/KR910700075A/ko not_active Withdrawn
- 1990-02-12 AT AT90301441T patent/ATE123952T1/de not_active IP Right Cessation
- 1990-02-12 CA CA002026312A patent/CA2026312A1/en not_active Abandoned
- 1990-02-12 HU HU901641A patent/HUT56288A/hu unknown
- 1990-02-12 NZ NZ232490A patent/NZ232490A/en unknown
- 1990-02-12 JP JP2503004A patent/JP2975676B2/ja not_active Expired - Lifetime
- 1990-02-12 WO PCT/GB1990/000213 patent/WO1990009195A1/en not_active Ceased
- 1990-02-12 AU AU50475/90A patent/AU632536B2/en not_active Ceased
- 1990-02-12 IL IL93361A patent/IL93361A0/xx unknown
- 1990-02-12 DE DE69020182T patent/DE69020182T2/de not_active Expired - Lifetime
- 1990-02-12 EP EP90301441A patent/EP0384624B1/en not_active Expired - Lifetime
- 1990-02-12 IE IE49490A patent/IE67320B1/en not_active IP Right Cessation
- 1990-02-12 FI FI904974A patent/FI904974A0/fi not_active Application Discontinuation
- 1990-10-09 NO NO90904367A patent/NO904367L/no unknown
- 1990-10-09 GB GB9021894A patent/GB2237020B/en not_active Revoked
Also Published As
| Publication number | Publication date |
|---|---|
| EP0384624A2 (en) | 1990-08-29 |
| EP0384624B1 (en) | 1995-06-21 |
| DE69020182D1 (de) | 1995-07-27 |
| JPH03504644A (ja) | 1991-10-09 |
| HUT56288A (en) | 1991-08-28 |
| NO904367L (no) | 1990-12-06 |
| EP0384624A3 (en) | 1990-11-14 |
| AU632536B2 (en) | 1993-01-07 |
| AU5047590A (en) | 1990-09-05 |
| KR910700075A (ko) | 1991-03-13 |
| IL93361A0 (en) | 1990-11-29 |
| CA2026312A1 (en) | 1990-08-11 |
| IE67320B1 (en) | 1996-03-20 |
| FI904974A7 (fi) | 1990-10-09 |
| GB8903022D0 (en) | 1989-03-30 |
| HU901641D0 (en) | 1991-03-28 |
| JP2975676B2 (ja) | 1999-11-10 |
| DE69020182T2 (de) | 1995-11-30 |
| FI904974A0 (fi) | 1990-10-09 |
| NO904367D0 (no) | 1990-10-09 |
| GB9021894D0 (en) | 1990-11-28 |
| GB2237020A (en) | 1991-04-24 |
| WO1990009195A1 (en) | 1990-08-23 |
| ATE123952T1 (de) | 1995-07-15 |
| IE900494L (en) | 1990-08-10 |
| NZ232490A (en) | 1992-09-25 |
| GB2237020B (en) | 1993-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI904975A0 (fi) | Tvaerbindade antikroppar och foerfaranden foer deras framstaellning. | |
| ZA90983B (en) | Cross-linked antibodies | |
| GB9824632D0 (en) | Biological compounds | |
| EP0323805A3 (en) | Novel antibodies | |
| ES2102007T3 (es) | Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras. | |
| BR0009323A (pt) | Anticorpos humanos que ligam a il-12 humana e métodos para a produção | |
| BR9916207A (pt) | Composições e métodos para terapia e diagnósticode câncer ovariano | |
| DE69232309D1 (de) | Weitgehend reine rezeptorartige, tgf-beta-1-bindende moleküle und deren verwendungen | |
| ATE255633T1 (de) | Humane b-lymphoblastoiden zellinie welche anti- gangliosid-antikörper sekretiert | |
| GB2278357B (en) | Humanised antibodies directed against A33 antigen | |
| DK402485D0 (da) | Tumorterapeutiskum og fremgangsmaade til dets fremstilling | |
| Rhind | Crosslinked antibodies and processes for their preparation |